Targeted radiation plus immunotherapy tested before prostate cancer surgery
NCT ID NCT06388369
Summary
This study tested if adding a new treatment before surgery could help men with very high-risk prostate cancer. The treatment combined a targeted radiation drug (LuPSMA) with or without an immunotherapy drug (ipilimumab). The main goals were to see if surgery could still happen on schedule and if the treatment could completely clear the cancer from the removed prostate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERY HIGH RISK PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Essen, Clinic of Urology
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.